Educated Patient® Breast Cancer Summit at MBCC Genetic Testing Presentation: March 4, 2023

Video

Watch Dr. Susan Domchek, from Penn Medicine, discuss genetic testing during the CURE Educated Patient® Breast Cancer Summit at MBCC.

As genetic testing becomes more available — and affordable — for patients with cancer, it is essential to discuss results with health care teams to better understand the significance, explained Dr. Susan Domchek.

“Cancer is a disease of genetic abnormalities,” Domchek, executive director of the Basser Center for BRCA and director of the MacDonald Women’s Cancer Risk Evaluation Center at Penn Medicine in Philadelphia, said in a presentation at the CURE® Educated Patient® Breast Cancer Summit, held live and virtually at the Miami Breast Cancer Conference.

There are two types of genetic mutations that clinicians look for: somatic, which are acquired mutations that occur in the tumor and cannot be passed down to offspring, and germline mutations, which are inherited and found in all cells throughout the body.

Educated Patient® Breast Cancer Summit at MBCC

Educated Patient® Breast Cancer Summit at the Miami Breast Cancer Conference, held March 4, 2023.

“When we talk about genetics, we often just throw it all up as the same thing, but it's really important to differentiate genetic mutations in tumors from the gene mutations that you're born with,” Domchek said.

The first step a patient should take in genetic testing is talking with their provider to determine if they are eligible for it. Current recommendations insist that anyone with metastatic breast cancer, triple-negative disease, those with Ashkenazi Jewish heritage, or those with a family history of ovarian, pancreatic or metastatic prostate cancer should be tested.

“The important thing here is not to memorize this list, the important thing is to ask your physicians whether it would be helpful for you to undergo germline testing in your care,” Domchek said.

Insurance typically covers testing for recommended patients, and the average cost is about $80, Domchek noted. If someone is not eligible for testing — such as those with early-stage breast cancer — there are other genetic testing options available for approximately $250.

When the results come back, Domchek mentioned that “not all genes are made equal,” and only some genetic mutations will affect treatment. Namely, if genetic testing comes back stating that a disease has a mutation in the BRCA1, BRCA2 or PALB2 gene, then the patient would be eligible for treatment with a PARP inhibitor.

Additionally, patients with ATM or CHEK2 mutations may be recommended to have a bilateral mastectomy — a surgery to have the tissue from both breasts removed — to prevent a secondary diagnosis.

However, Domchek mentioned that there may not be an increased risk for patients with an ATM mutation, and that those with CHEK2 mutations have about a 20% increased risk of a secondary breast cancer over 20 years.

“So all these factors need to be considered. And again, it's really important to have posttest education to to talk about what all this means,” Domchek said.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of a woman with black hair.
Image of a woman with brown shoulder-length hair in front of a gray background that says CURE.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Kim in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Related Content
Image of FDA approval, what you need to know.

Enhertu Marks First Therapy Approved Across HER2-Positive Solid Tumors

April 24th 2024
Article

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

Read More

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

February 5th 2024
Podcast

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

Listen

Illustration of a woman with shoulder-length hair wearing a red cardigan.

The Sudden Twists and Turns of Cancer

April 19th 2024
Article

Finding support as a cancer survivor helps me get through the unpredictable twists and turns of cancer.

Read More

cancer horizons image for podcast

Conference Highlights from the 2023 ASH Annual Meeting

December 14th 2023
Podcast

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

Listen

Image of a doctor holding treatment on an IV pole.

What Patients With Breast Cancer Need to Know About ADC-Related Fatigue

April 17th 2024
Article

Researchers have found that treatment with antibody-drug conjugates is associated with fatigue among patients with breast cancer.

Read More

Illustration of a woman with light brown hair, glasses and a blue floral top.

Advocating for My Brain After Metastases from Breast Cancer

April 17th 2024
Article

My metastatic breast cancer has caused metastases to my brain, so it's important I advocate for my brain when symptoms arise.

Read More